GAJ - International HIV & Hepatitis Virus Drug Resistance Presentations





		International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies Selected Slide Presentations Click on the links below to view presentations. Resistance to New Antiretroviral Agents Plenary Presentation: Influenza Resistance Menno de Jong; University of Amsterdam, the Netherlands Mutations Based on Viral Decay Acceleration in the HIV-1 Genomes of a Clinical Population Treated with the Mutagenic Nucleoside KP1461 James Mullins; University of Washington, USA The Crystal Structure of EFdA-Resistant HIV-1 Reverse Transcriptase Reveals Structural Changes in the Polymerase Active Site Bruno Marchand; University of Missouri, USA Temporal Order of Resistance Emergence for Lamivudine/Emtricitabine, Efavirenz, and Raltegravir in Treatment-Naïve Patients Michael Miller; Merck & Co., Inc., USA Strong Inhibition of Wild-Type and Integrase Inhibitor (INI)-Resistant HIV Integrase (IN) Strand Transfer Reaction by the Novel INI S/GSK1349572 Tomokazu Yoshinaga; Shionogi, Japan Mechanisms of HIV Drug Resistance The K65R Mutation in Subtype B and C HIV-1: Rates of Development and the Implications of Template-Specific Dislocation Mutagenesis Dimitrios Coutsinos; McGill University AIDS Centre, Canada S/GSK1349572 Demonstrates Significantly Slower Dissociation Rates than Raltegravir when Comparing Wild Type and Raltegravir Resistant Integrase Protein Kendra Hightower; GlaxoSmithKline, USA Genotypic and Phenotypic Markers of Response to Entry Inhibitors Specific Genetic Signatures in V3 Base Can Modulate Co-receptor Usage in Vivo, the Interaction with Neutralizing Antibodies, and HIV-1 Cytopathic Effect Valentina Svicher; University of Rome Tor Vergata, Italy Pairwise Comparison of Genotypic Tropism Prediction between One Reference Center and 10 European Laboratories Rolf Kaiser; University of Cologne, Germany HBV Drug Resistance Plenary Presentation: Hepatitis B: New Treatments and Drug Resistance Stephen Locarnini; Victorian Infectious Diseases Reference Laboratory (VIDRL), Australia The HBV Genetic Barrier and the Overlapping Structure of HBV Genome Synergistically Modulate Drug Resistance Emergence and Immune Escape Potential of HBV Genotypes Valentina Svicher; University of Rome Tor Vergata, Italy HCV Drug Resistance Plenary Presentation: Hepatitis C: New Treatments and Drug Resistance Jean-Michel Pawlotsky; Hôpital Henri Mondor, Université Paris, France Analysis of Resistance in Virologic Failures during IFN/RBV Therapy Post 28 Day Treatment with MK7009; Results through Week 24 of the Phase 2A Dosing Finding Study in Genotype 1 Patients Richard Barnard; Merck and Co., USA Resistance Profile of the Novel Hepatitis C Virus (HCV) Acyclic Nucleoside Phosphonate Inhibitor ODE-S-MPMPA David Wyles; University of California San Diego, USA Deep Sequencing Analysis of Baseline and on Treatment Samples from HCV Genotype 1 Patients Treated for 5 Days with TMC435 Monotherapy and Subsequently Re-treated with TMC435 in Combination with PegIFNa 2a/Ribavirin Oliver Lenz; Tibotec BVBA, Belgium Selection and Characterization of Hepatitis C Virus Replicons Using Combination of NS3 Protease and NS5B Non-nucleoside Inhibitors or Combination of NS5B Nucleotide Inhibitors Angela Lam; Pharmasset Inc., USA Molecular Characterization of HCV Resistance to Telaprevir, a Novel, Potent HCV Protease Inhibitor Stephane Chevaliez; Henri Mondor Hospital, France Application of New Sequencing Techniques Next Generation Deep Sequencing Technologies for Virus Quasispecies Analysis: Implications for Detecting Minority Drug Resistant Variants Robert Shafer; Stanford University, USA Reduced PCR-based Recombination for HIV-1 Drug Resistance Mutation Linkage Determination by 454 Pyrosequencing Wei Shao; ABCC, SAIC Frederick, NCI Frederick, USA Prevalence of Low-level Variants with RT K65R among Different HIV Subtypes and the Effects of ARV-exposure on Variant Levels Michael Kozal; Yale University School of Medicine and VA CT, USA Presence of Low Abundance Drug Resistant Mutations in Recently Infected HIV Subtype C Patients from South Africa Carole Wallis; University of the Witwatersrand, South Africa Single Transmitted Drug Resistance Mutations: Not Always an Indicator of Transmission of More Extensive Resistance Profiles Marieke Pingen; Erasmus Medical Center and University Medical Center Utrecht, the Netherland A Multicenter Collaborative Study on HIV Drug Resistance Testing using 454 Massively Parallel Pyrosequencing Martin Däumer; Institute of Immunology and Genetics, Germany HIV Pathogenesis, Fitness and Resistance HIV-1 Drug Resistance Evolution During Persistent Near Target Viral Suppression Babafemi Taiwo; Northwestern University, USA Complete Protection against Rectal Transmission of an Emtricitabine (FTC)-Resistant SHIV162p3M184V Mutant by Intermittent Prophylaxis with Truvada J. Gerardo Garcia-Lerma; Centers for Disease Control and Prevention, USA Analysis of HIV DNA Molecules in Paired Peripheral Blood and Lymph Node Tissue Samples from Chronically Infected Patients Sarah Palmer; Swedish Institute for Infectious Disease Control, Karolinska Institute, Sweden The Relationship between Virus Replication and Gene Expression in Lymphatic Tissue during HIV-1 Infection Anthony Smith; University of Minnesota, USA Persistence, Reservoirs and Elimination Strategies The Histone Deacetylase Inhibitors SAHA, MS-275, LBH589 and MCT3 are able to Induce HIV-1 Transcription with Differing Potencies in Chronically Infected Cell Lines and Latently Infected Primary CD4+ T-cells Fiona Wightman; Monash University, Australia Emergence of Monotypic HIV-1 DNA during ART Suggests Proliferation of Cells with Integrated HIV DNA Provirus May Sustain Infection Thor Wagner; Seattle Children's Hospital, University of Washington, USA Epidemiology Dynamic Expression of HIV-1 Drug Resistance Mutations during Acute Infection Jeffrey Johnson; Centers for Disease Control and Prevention, USA Large Scale Phylodynamics of HIV-1 in Italy: Analysis on Epidemic and Resistance Transmission Mattia Prosperi; Catholic University of Sacred Heart, Italy The Effect of Transmitted HIV-1 Drug Resistance on Pre-therapy Viral Load David Dunn; MRC Clinical Trials Unit, UK Prevalence of HIV-1 Drug Resistance-associated Mutations in a Large Cohort of Antiretroviral-naive HIV-infected Individuals in the United States from 2000-2009 Lisa Ross; GlaxoSmithKline, USA Rapid Accumulation of Drug Resistance and Loss of Therapeutic Options Precede WHO Defined Criteria for Treatment Failure Annemarie Wensing; University Medical Center Utrecht, the Netherlands